FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2774825032> ?p ?o ?g. }

• W2774825032 endingPage "1049.e5" @default.
• W2774825032 startingPage "1036" @default.
• W2774825032 abstract "BackgroundImmunodysregulation polyendocrinopathy enteropathy x-linked (IPEX) syndrome is a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (IS), have not been thoroughly examined.ObjectiveThis analysis sought to evaluate disease onset, progression, and long-term outcome of the 2 main treatments in long-term IPEX survivors.MethodsClinical histories of 96 patients with a genetically proven IPEX syndrome were collected from 38 institutions worldwide and retrospectively analyzed. To investigate possible factors suitable to predict the outcome, an organ involvement (OI) scoring system was developed.ResultsWe confirm neonatal onset with enteropathy, type 1 diabetes, and eczema. In addition, we found less common manifestations in delayed onset patients or during disease evolution. There is no correlation between the site of mutation and the disease course or outcome, and the same genotype can present with variable phenotypes. HSCT patients (n = 58) had a median follow-up of 2.7 years (range, 1 week-15 years). Patients receiving chronic IS (n = 34) had a median follow-up of 4 years (range, 2 months-25 years). The overall survival after HSCT was 73.2% (95% CI, 59.4-83.0) and after IS was 65.1% (95% CI, 62.8-95.8). The pretreatment OI score was the only significant predictor of overall survival after transplant (P = .035) but not under IS.ConclusionsPatients receiving chronic IS were hampered by disease recurrence or complications, impacting long-term disease-free survival. When performed in patients with a low OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor source, or conditioning regimen. Immunodysregulation polyendocrinopathy enteropathy x-linked (IPEX) syndrome is a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (IS), have not been thoroughly examined. This analysis sought to evaluate disease onset, progression, and long-term outcome of the 2 main treatments in long-term IPEX survivors. Clinical histories of 96 patients with a genetically proven IPEX syndrome were collected from 38 institutions worldwide and retrospectively analyzed. To investigate possible factors suitable to predict the outcome, an organ involvement (OI) scoring system was developed. We confirm neonatal onset with enteropathy, type 1 diabetes, and eczema. In addition, we found less common manifestations in delayed onset patients or during disease evolution. There is no correlation between the site of mutation and the disease course or outcome, and the same genotype can present with variable phenotypes. HSCT patients (n = 58) had a median follow-up of 2.7 years (range, 1 week-15 years). Patients receiving chronic IS (n = 34) had a median follow-up of 4 years (range, 2 months-25 years). The overall survival after HSCT was 73.2% (95% CI, 59.4-83.0) and after IS was 65.1% (95% CI, 62.8-95.8). The pretreatment OI score was the only significant predictor of overall survival after transplant (P = .035) but not under IS. Patients receiving chronic IS were hampered by disease recurrence or complications, impacting long-term disease-free survival. When performed in patients with a low OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor source, or conditioning regimen." @default.
• W2774825032 created "2017-12-22" @default.
• W2774825032 creator A5001156641 @default.
• W2774825032 creator A5002489212 @default.
• W2774825032 creator A5003114766 @default.
• W2774825032 creator A5005040866 @default.
• W2774825032 creator A5006102363 @default.
• W2774825032 creator A5006672507 @default.
• W2774825032 creator A5009832583 @default.
• W2774825032 creator A5012019419 @default.
• W2774825032 creator A5013427760 @default.
• W2774825032 creator A5013983797 @default.
• W2774825032 creator A5014943816 @default.
• W2774825032 creator A5018805770 @default.
• W2774825032 creator A5019205144 @default.
• W2774825032 creator A5020414450 @default.
• W2774825032 creator A5020617631 @default.
• W2774825032 creator A5021572787 @default.
• W2774825032 creator A5022405285 @default.
• W2774825032 creator A5022712318 @default.
• W2774825032 creator A5024491954 @default.
• W2774825032 creator A5026301065 @default.
• W2774825032 creator A5026579222 @default.
• W2774825032 creator A5026927916 @default.
• W2774825032 creator A5027649001 @default.
• W2774825032 creator A5027756646 @default.
• W2774825032 creator A5027980182 @default.
• W2774825032 creator A5028070594 @default.
• W2774825032 creator A5028236128 @default.
• W2774825032 creator A5028292912 @default.
• W2774825032 creator A5028591438 @default.
• W2774825032 creator A5029680324 @default.
• W2774825032 creator A5030314619 @default.
• W2774825032 creator A5030358067 @default.
• W2774825032 creator A5030620194 @default.
• W2774825032 creator A5030851924 @default.
• W2774825032 creator A5030953316 @default.
• W2774825032 creator A5032842298 @default.
• W2774825032 creator A5033104475 @default.
• W2774825032 creator A5034487270 @default.
• W2774825032 creator A5036578375 @default.
• W2774825032 creator A5038630174 @default.
• W2774825032 creator A5042125969 @default.
• W2774825032 creator A5042544416 @default.
• W2774825032 creator A5044105377 @default.
• W2774825032 creator A5044799435 @default.
• W2774825032 creator A5047178145 @default.
• W2774825032 creator A5048120651 @default.
• W2774825032 creator A5048349754 @default.
• W2774825032 creator A5051621566 @default.
• W2774825032 creator A5052243411 @default.
• W2774825032 creator A5052357377 @default.
• W2774825032 creator A5055036012 @default.
• W2774825032 creator A5055400659 @default.
• W2774825032 creator A5056887177 @default.
• W2774825032 creator A5056892740 @default.
• W2774825032 creator A5057064072 @default.
• W2774825032 creator A5062214611 @default.
• W2774825032 creator A5063016319 @default.
• W2774825032 creator A5063290921 @default.
• W2774825032 creator A5063472080 @default.
• W2774825032 creator A5064058270 @default.
• W2774825032 creator A5064708020 @default.
• W2774825032 creator A5064848473 @default.
• W2774825032 creator A5065464020 @default.
• W2774825032 creator A5066241741 @default.
• W2774825032 creator A5067900541 @default.
• W2774825032 creator A5068439726 @default.
• W2774825032 creator A5068516471 @default.
• W2774825032 creator A5069128648 @default.
• W2774825032 creator A5069358263 @default.
• W2774825032 creator A5069417543 @default.
• W2774825032 creator A5069875702 @default.
• W2774825032 creator A5075839647 @default.
• W2774825032 creator A5078465262 @default.
• W2774825032 creator A5079302040 @default.
• W2774825032 creator A5079634281 @default.
• W2774825032 creator A5082712272 @default.
• W2774825032 creator A5082815899 @default.
• W2774825032 creator A5083186666 @default.
• W2774825032 creator A5085211757 @default.
• W2774825032 creator A5087818948 @default.
• W2774825032 creator A5089123620 @default.
• W2774825032 creator A5089140696 @default.
• W2774825032 creator A5089701447 @default.
• W2774825032 date "2018-03-01" @default.
• W2774825032 modified "2023-10-18" @default.
• W2774825032 title "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study" @default.
• W2774825032 cites W1194989569 @default.
• W2774825032 cites W1486722793 @default.
• W2774825032 cites W1499151513 @default.
• W2774825032 cites W1966289025 @default.
• W2774825032 cites W1998157143 @default.
• W2774825032 cites W2007357755 @default.
• W2774825032 cites W2015273879 @default.
• W2774825032 cites W2017712914 @default.
• W2774825032 cites W2017798195 @default.
• W2774825032 cites W2022955078 @default.

• next